ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,272.43
-0.10%
US Tech 100
18,039.20
0.06%
다우존스 지수
38,496.15
-0.49%
Bitcoin
69,137.37
2.05%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Kinnate Biopharma Inc (KNTE)

  7. Kinnate Biopharma Inc (KNTE) 뉴스

KNTE

Kinnate Biopharma (KNTE)

Kinnate Biopharma Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:KNTE
일자시간출처헤드라인심볼기업
2024/04/0322:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:KNTEKinnate Biopharma Inc
2024/03/2005:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
2024/03/0607:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0607:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0507:27Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0122:53Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0122:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0122:35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0122:35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0122:35PR Newswire (Canada)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
2024/03/0122:30GlobeNewswire Inc.Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
2024/02/2120:01Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
2024/02/1707:57PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
2024/02/1700:46PR Newswire (US)Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law FirmNASDAQ:KNTEKinnate Biopharma Inc
2024/02/1623:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
2024/02/1622:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:KNTEKinnate Biopharma Inc
2024/02/1622:00GlobeNewswire Inc.Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareNASDAQ:KNTEKinnate Biopharma Inc
2024/02/1423:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNTEKinnate Biopharma Inc
2024/01/1706:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
2023/12/0607:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
2023/12/0607:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
2023/11/1523:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
2023/11/1006:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
2023/11/1006:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
2023/11/1006:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
2023/09/1905:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
2023/09/1905:10GlobeNewswire Inc.Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringNASDAQ:KNTEKinnate Biopharma Inc
2023/09/0706:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
2023/09/0706:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
2023/08/0905:48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
 검색 관련기사 보기:NASDAQ:KNTE

최근 히스토리

USOTC
XMSCF
XTtrackers (GM)
EU
XS2696124366
ING Bank NV Ingbk3.655%2...
TG
ROM
Rohm
EU
FR2CIBFS0136
Credit Agricole CIB Fina...
OKEX
GNXETH
COIN
NSDUSD
Nasdacoin
BOV
RDNI3R
RNI ON
USOTC
TRSBF
3SBio (PK)
EU
BE0002993740
Belfius Bank SA Bond 375...
NASDAQ
FSVOX
Fidelity Advisor Sustain...
BIT
UB4Q75
Unicredit Bank
NYSE
DCUC
Dominion Resources, Inc.
EU
BE6333696811
Leudelange 1 srl Leudela...
BIT
P20WK4
NLBNPIT20WK4 20241220 190
USOTC
TTNDF
Techtronic Inc Comp (QX)
LSE
BS66
Stand.chart.u
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유